Cancers, Vol. 10, Pages 519: EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma

In this study, we assessed the efficacy of EphA3 antibody drug conjugate (ADC) and radioimmunotherapy (RIT) approaches using orthotopic animal xenograft models. Brain uptake studies, using positron emission tomography/computed tomography (PET/CT) imaging, show EphA3 antibodies are effectively delivered across the blood-tumour barrier and accumulate at the tumour site with no observed normal brain reactivity. A robust anti-tumour response, with no toxicity, was observed using EphA3, ADC, and RIT approaches, leading to a significant increase in overall survival. Our current research provides evidence that GBM patients may benefit from pay-loaded EphA3 antibody therapies.

Source: Cancers - December 17, 2018 Category: Cancer & Oncology Authors: Carolin Offenh äuser Fares Al-Ejeh Simon Puttick Kathleen S. Ensbey Zara C. Bruce Paul R. Jamieson Fiona M. Smith Brett W. Stringer Benjamin Carrington Adrian V. Fuchs Craig A. Bell Rosalind Jeffree Stephen Rose Kristofer J. Thurecht Andrew W. Boyd Bryan Tags: Article Source Type: research